2009:

1. Ryan P, Resino S, Miralles P, Cosín J, López JC, Moreno S, Catalán P, Ramírez M, Gutiérrez I, and Berenguer J. Insulin Resistance Impairs Sustained Virologic Response to Interferon plus Ribavirin in HIV/HCV Co-infected Patients. 16^th Conference on Retroviruses and Opportunistic Infections (CROI 2009). Montreal, Canada. February 8-11, 2009.

2. Vispo E, Madejon A, Tuma P, Medrano J, Resino S, Rodriguez V, Labarga P, Martin-Carbonero L, Barreiro P, and Soriano V Effect of a Widely Used HCV Therapy on the Current Distribution of HCV Genotypes in a Large Cohort of HIV/HCV-co-infected Patients in Spain. 16^th Conference on Retroviruses and Opportunistic Infections (CROI 2009). Montreal, Canada. February 8-11, 2009.

2008:

3. Medrano J, Resino S, Vispo E, Tuma P, Labarga P, García-Samaniego J, Barreiro P, Soriano V. HCV Relapse after Peg-Interferon (IFN) plus Ribavirin (RBV): Is 12-week Control Enough to Determine HCV Clearance? Ninth International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 09 – 13 November 2008.

4. Resino S, Miralles P, Micheloud D, Bellón JM, Vargas A, Catalán P, Álvarez E, Cosín J, Lorente R, Sánchez-Conde M, Muñoz-Fernández MA, and Berenguer J. Diagnostic Accuracy of Serum Hyaluronic Acid for Advanced Fibrosis/Cirrhosis in Patients Coinfected with HIV and HCV. 48^th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46^th Annual Meeting. Washington, DC, USA. October 25-28, 2008.

5. Resino S, Micheloud D, Miralles P, Bellón JM, Catalán P, Álvarez E, Cosín J, Lorente R, Sánchez-Conde M, Muñoz-Fernández MA, and Berenguer J. HGM3, a new serum index that accurately predicts bridging fibrosis and cirrhosis in HIV and HCV co-infected patients. XVII International AIDS Conference. Mexico City, Mexico, 3-8 August 2008.

6. Medrano J, Resino S, Tuma P, Vispo E, Tuma P, Labarga P, García-Samaniego J, Barreiro P, Soriano V. HCV relapses after peg-interferon (IFN) plus ribavirin (RBV) therapy: Is 12-week assessment upon completion treatment enough to determine sustained clearance? HIV Liver Disease 2008. Jackson Lake Lodge, Wyoming, USA, 25-27 Sepstmber 2008.

7. Seoane E, Resino S, Mohedano E, Alcorta AR, Moreno S, Lopez Bernaldo de Quiros JC, Rubio R, Gonzalez-García J, Muñoz-Fernández MA. Immumnological predictor of CD4+ T-cell decline in antiretroviral treatment interruption. XXVII EAACI Congress of the European Academy of Allergology and Clinical Immunology. Barcelona, Spain. 7-11 June 2008.

8. Ryan P, Berenguer J, Miralles P, Michelaud D, Catalan P, Bellon JM, Sanchez-Conde M, Alvarez E, Munoz MA, Resino S. Insulin resistance is independently associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients. 43^rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy. 23-27 April 2008.

2007:

9. Micheloud D, Salcedo M, Resino S, Rincón D, Alvarez E, Clemente G, Catalina MV, Gomez-Camarero J, Lorente R, Muñoz-Fernández MA, Bañares R. Serum levels of fibrosis progression biomarkers measured early after LT are associated to severe HCV recurrence.  The Liver Meeting® 2007 (58^th Annual Meeting of the American Association for the Study of Liver Diseases). Boston, Massachusetts, USA, November 2-6, 2007.

10. Resino S, Micheloud D, Larrú B, Jensen J, Bellón JM, Léon JA, Resino R,  de José MI, Gurbindo D, Mellado MJ, Guillen S, Ramos JT, Muñoz-Fernández MA. Slow and not complete immunological recovery in severe immunodeficiency HIV-1 infected children after 8 years on highly active antiretroviral therapy. 11^th European AIDS Conference/EACS. Madrid, Spain, October 24-27, 2007.

11. Berenguer J, Resino S, Miralles P, Bellón JM, Sánchez-Conde M, López JC, Cosín J, Padilla B, Catalán P, Alvarez E. Association between Nevirapine exposure and reduced liver fibrosis progression and development of bridging fibrosis and cirrhosis in HIV/HCV-coinfected patients. 47^th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC™). Chicago, IL , USA, September 17-20, 2007. ORAL.

12. González-Rivera M, Resino S, Muñoz-Fernández M.A. Peripheral T cell subsets profiles associated with virological phenotype of HIV isolate in heavily pretreated HIV-1 vertically infected children. 4^th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007). Sydney, Australia. July 22-25, 2007.

13. González-Rivera M, Resino S, Muñoz-Fernández M.A. GP 120 V3 loop: specific amino acids were associated to CD4+T cells and viral load values in HIV-1 vertically infected children. 4^th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007). Sydney, Australia. July 22-25, 2007.

14. Larru B, De José MI, Bellón JM, Resino S, Fortuny C, Tomás JT, Navarro M, Gurbindo MD, Soler  P, Leal JA, Mellado MJ, Muñoz MA. Long term use of lopinavir among children. 25^th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Porto, Portugal, May 2- 4, 2007.

15. Resino S, Berenguer J, Miralles P, Bellón JM, Sánchez-Conde M, López JC, Cosín J, Padilla B, Catalán P, and Álvarez E. HAART reduces the fibrosis progression rate and the development of bridging fibrosis and cirrhosis in HIV/HCV-coinfected patients. 14^th Conference on Retroviruses and Opportunistic Infections (CROI). Los Angeles, USA, Febreary 25-28, 2007.

2006:

16. Resino S, Berenguer J, Bellón JM, Micheloud D, Miralles P, Lopez-Bernaldo de Quiros JC, Cosín J, Muñoz-Fernández MA. Influence of Age in HIV-Infection Outcomes among Antiretroviral-Naive Patients with Severe Immunodeficiency during Highly Active Antiretroviral Therapy. 46^th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC™). San Francisco, USA, September 27-30, 2006.

17. Micheloud D, Jensen J, Gurbindo MD, Ramos JT, de José MI, Martín-Fontelos P, Moreno Perez D, Muñoz-Fernández MA, Resino S. The natural history of children co-infected HVC and HIV. 46th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC™). San Francisco, USA, September 27-30, 2006.

18. Berenguer J, Miralles P, Alvarez E, Bellón JM, Sánchez Conde M, López JC, Cosín J, Gutiérrez I, Ramírez M, Catalán P, Resino S. Identification of Liver Fibrosis in HIV/HCV Coinfected Patients with a Simple Predictive Model Based on Routine Laboratory Data. 46th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC™). San Francisco, USA, September 27-30, 2006.

19. Resino S, Seoane E, Gurbindo MD, León JA, Muñoz-Fernández MA. CD4+ T-cells immunodeficiency is more dependent of immune activation than viral load in HIV-infected children on highly active antiretroviral therapy. 1^st Joint Meeting of European National Societies of Immunology and 16^th European Congress of Immunology. Paris, France, September 6-9, 2006.

20. Micheloud D, Salcedo M, Rincon D, Bañares R, Resino S, Tejeiro R, Rodriguez J, Gil J, Alvarez A, Fernandez-Cruz E, Carbone J. Humoral and cellular immunity parameters maight be predictor of early infection alter liver transplantation. 1^st Joint Meeting of European National Societies of Immunology and 16^th European Congress of Immunology. Paris, France, September 6-9, 2006.

21. Seoane E; Resino S; Moreno S, Lopez Bernaldo de Quiros JC, Moreno A, Rubio R, Gonzalez J, Pulido F, Muñoz-Fernández MA. Lymphoproliferative response to PPD “in vitro” is predictor of CD4+ decrease in HIV-1 treatment interruption. 1^st Joint Meeting of European National Societies of Immunology and 16^th European Congress of Immunology. Paris, France, September 6-9, 2006.

22. Larrú B, Resino S, Bellón JM, Resino R, Gurbindo MD, León JA, Ramos JT, Ciria L, de José MI, Mellado MJ, Muñoz-Fernández MA. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1-infected children: 3 years of follow-up. XVI International AIDS Conference. Toronto, Canadá, 13-18 August 2006.

23. Resino S, Seoane E, Gurbindo MD, León JA, Muñoz-Fernández MA. CD4+ T-cells immunodeficiency is more dependent of immune activation than viral load in HIV-infected children on highly active antiretroviral therapy. XVI International AIDS Conference. Toronto, Canadá, 13-18 August 2006.

24. Perez A, Gurgindo MD, Resino S, Aguaron A, and Muñoz-Fernández MA. Sequential development of immune system along gestation: lymphocyte subsets study. XXV Congress of the European Academy of Allergology and Clinical Immunology. Vienna, Austria, 10-14 June 2006.

25. Micheloud D, Salcedo M, Rincon D, Resino S, Urrea R, Rodriguez-Molina JJ, Gil J, Alvarez A, Sarmiento E, Fernandez-Cruz E, Carbone J. Humoral and cellular immunity parameters as risk factors of infection after liver transplantation. 7th International Conference on New Trend in Immunosupression and Immunetherapy. Berlin, Germany, Febreury, 2006.

2005:

26. Perez A, Díaz L, Jímenez JL, Gurgindo MD, Resino S, Aguaron A, and Muñoz-Fernández MA. Evolution of the immune system along gestation: analysis of T-cell reperoire. 13th European Workshop on Neonatology. Freiburg, Germany, October, 2005.

27. Perez A, Alvaro-Meca, A, Gurgindo MD, Seoane E, Resino S, Aguaron A, Villa I, and Muñoz-Fernández MA. Sequential development of the immune system along gestation: Lymphocyte subsets study. 13th European Workshop on Neonatology. Freiburg, Germany, October, 2005.

28. Resino S, Resino R, Bellón JM, Alvaro-Meca A, Gurbindo MD, de José MI, Ramos JT, Martín Fontelos P, Ciria L, and Muñoz-Fernández MA. Clinical outcomes improves with the highly active antirretroviral therapy on vertically HIV-1 infected children. 3^rd IAS Conference of HIV pathogenesis and Treatment. Rio de Janeiro, Brasil, July 24-27, 2005.

29. Resino S, Seoane E, Perez A, Ruiz-Mateos E, Galán I, Leal M, and Munoz-Fernandez M. Different profiles of immune reconstitution in children and adults with HIV-infection after HAART. 3^rd IAS Conference of HIV pathogenesis and Treatment. Rio de Janeiro, Brasil, July 24-27, 2005.

30. Resino S, Perez A, Alvaro-Meca A, León JA, Gurbindo MD, and Muñoz-Fernández MA. Plasma interleukin-7 levels before highly active antiretroviral therapy may predict CD4+ T-cells recovery in HIV-children. 5^th Annual Meeting of FOCIS. Boston, USA, July 12-16 2005.

31. Resino S, Seoane E, Perez A, Ruiz-Mateos E, Galán I, Leal M, and Munoz-Fernandez M. Different profiles of immune reconstitution in children and adults with HIV-infection after HAART. 5^th Annual Meeting of FOCIS. Boston, USA, July 12-16 2005.

2004:

32. Berenguer J, Perez-Elias MJ, Resino S, Knobel H, Rivas-Gonzlez P, and Gatell JM. Abacavir, lamivudine and zidovudine (ALZ) in antiretroviral-nave HIV-infected patients with profound immunosuppression (CD4+ cells <100/mm³): a multicenter observational study. Seventh International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, UK. September 2004.

33. Galán I, Jimenez JL, Gonzalez-Rivera M, de Jose MI, Navarro M, Ramos JT, Mellado MJ, Gurbindo D, Bellon JM, Resino S, Cabrero E, and Munoz-Fernandez MA. Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. XV International AIDS Conference. Bangkok, Thailand, July 11-16, 2004.

34. Resino S, Bellon JM, Galán I, Ramos JT, Gonzalez-Rivera M, de Jose JM, Gonzalez I, Gurbindo D, Mellado MJ, Cabrero E, and Munoz-Fernandez MA. Positive virologic outcome after Lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children. A prospective cohort study. XV International AIDS Conference. Bangkok, Thailand, July 11-16, 2004.

35. Perez A, Galán I, Resino S, Pajuelo L, Bellon JM, and Munoz-Fernandez M. Strong Association between Recovery of T Thymic Function, IL-7 and Switch in Viral Phenotype in HIV-1 infeted children on HAART. 12^th International Congress of Immunology and 4^th Annual Conference of FOCIS. Montreal, Canada, July 18-23 2004

36. Galán I, Jimenez JL, Gonzalez-Rivera M, de Jose MI, Navarro M, Ramos JT, Mellado MJ, Gurbindo D, Bellon JM, Resino S, Cabrero E, and Munoz-Fernandez MA. Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children. 12^th International Congress of Immunology and 4^th Annual Conference of FOCIS. Montreal, Canada, July 18-23 2004

37. Resino S, Bellon JM, Galán I, Ramos JT, Gonzalez-Rivera M, de Jose JM, Gonzalez I, Gurbindo D, Mellado MJ, Cabrero E, and Munoz-Fernandez MA. Positive virologic outcome after Lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children. A prospective cohort study. 12^th International Congress of Immunology and 4^th Annual Conference of FOCIS. Montreal, Canada, July 18-23 2004.

38. Diez JL, Balsalobre P, Miralles P, Gomez-Pineda A, Carrion R, Buño I, Resino S, Conde E, Ribera JM, Serrano D, Berenguer J on behalf on the Spanish cooperative groups GELTAMO and GESIDA. Efficacy of autologous stem cell transplant in aids-related lymphoma patients. 30^th Annual Meeting of the European Group for Blood and Marrow Transplantation. Barcelona, Spain March 28-31, 2004.

2003:

39. Ramos JT, Gonzalez Tome MI, Fortuny C, Otero MC, De José MI, Gurbindo MD, Navarro ML, Martín-Fontelos P, Mellado MJ, Pocheville I, Bertran JM, Mur A, Dueñas J, Gracia M, González-Montero R, Resino S, Muñoz-Fernández MA, and Cabrero E. Antiviral response at 12 months to lopinavir-ritonavir (Kaletra) HIV-infected children experienced with 3 classes of antiretrovirals. The 2nd IAS Conference on HIV Patogénesis and Treatment. Paris July 2003.

2002:

40. Resino S, Navarro ML, Correa R, Bellón JM, Gurbindo Gutierrez MD, Gómez-Campderá JA, and Muñoz-Fernández MA. Long-term asymptomatic vertically HIV-1 infected children have a similar functional immune system than uninfected children. 3^rd World Congress of Pediatric Infectious Diseases. Santiago, Chile. November 2002.

41. Sánchez-Ramón S, Rodriguez-Saiz C, Lozano N, Resino S, Muñoz C, Rodriguez-Mahou M, Muñoz-Fernández MA, de Andres C. Sequential study of serum sex hormones and Th1/Th2 balance during and after relapse of multiple sclerosis. ACTRIMS-ECTRIMS 2002. Baltimore, Maryland, USA. September 2002.

42. Ramos JT, Carreño P, Fortuny C, Orti A, De José MI, Mellado MJ, Pocheville I, Navarro ML, Resino S, Muñoz-Fernández MA, Bellón JM, Mur A, Dueñas J, Gracia M, González-Montero R, Tello LM, and Cabrero E. Response to lopinavir-ritonavir (Kaletra) in heavily pretreated children. XIV International AIDS Conference. Barcelona July 2002.

43. Sánchez-Ramón S, Resino S, Bellón JM, Contó-Nogués C, Gurbindo MD, Ramos JT, Rodríguez-Sáinz C, and Muñoz-Fernández MA. Low CD8+ T-lymphocyte counts and high circulating monocytes predating paediatric HIV-1-associated progressive encephalopathy: in the search of neuropathogenic markers. XIV International AIDS Conference. Barcelona (Spain). July 2002.

44. Sánchez-Ramón S, Resino S, Bellón JM, Contó-Nogués C, Gurbindo MD, Ramos JT, Rodríguez-Sáinz C, and Muñoz-Fernández MA. CD8+ T-lymphocyte counts and circulating monocytes as neuropathogenic markers of paediatric HIV-1-associated progressive encephalopathy.  7th ECEAR. Genoa (Italy).June 2002.

45. Resino S, Bellón JM, Sánchez-Ramón S, Correa R, Gurbindo MD, Navarro ML, Clemente J, and Muñoz-Fernández MA. Immune Reconstituion after Long-Term Antiretroviral Therapy in Pediatric AIDS. 7th ECEAR. Genoa (Italy).June 2002.

46. Sánchez-Ramón S, Resino S, Bellón JM, Contó-Nogués C, Gurbindo MD, Ramos JT, Rodríguez-Sáinz C, and Muñoz-Fernández MA. Low CD8+ T-lymphocyte counts predict HIV-1-associated progressive encephalopathy in children and may trigger CNS spread of HIV-1-activated monocytes. 9^th Conference on Retroviruses and Opportunistic Infections. Seattle (USA). February 2002.

2001:

47. Resino S, Navarro J, Bellón JM, Gurbindo MD, León JA, and Muñoz-Fernández MA. Recovery of T-cell subsets after highly active antiretroviral therapy in HIV-infected children. 6th ECEAR. Edinburgo (Escocia).June 2001.

48. Resino S, Abad ML, Navarro J, Bellón JM, Sánchez-Ramón S, and Muñoz-Fernández MA. Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers. 6th ECEAR. Edinburgh (Escocia).June 2001.

49. Jiménez JL, Resino S, González-Nicolás J, Alvarez S, Fresno M, and Muñoz-Fernández MA. Relationship among viral replication, TNF-alfa and nitric oxide in vertically infected children: implications for pathogenesis. 6th ECEAR. Edinburgh (Escocia).June 2001.

2000:

50. Muñoz-Fernández MA, Resino S, Bellón JM, Navarro J, Abad ML and Fernández-Cruz E. Correlation of CD8+ T Lymphocyte subpopulations with plasma viral load and CD4 in AR-treated vertically HIV-infected children: contribution of memory, effector and activated cells to HIV immunopathology. XIII International AIDS Conference. Durban (South Africa). July 2000.

51. Navarro J, Abad ML, Resino S, Jiménez JL, Cantó C, Carbone J, Lopez F, Esteban M, Muñoz-Fernández MA, E. Fernandez-Cruz for the spanish 2102 team. Augmentation of HIV-1-specific cytotoxic T lymphocytes and cellular immune responses in HIV-1 + individuals treated with a therapeutic vaccine plus antiretrovirals in a Phase II study: two year results. XIII International AIDS Conference. Durban (South Africa). July 2000.

52. Resino S, Bellón JM, Sánchez-Ramón S, Gurbindo MD, León JA, Ruíz-Contreras J, Ramos JT, and Muñoz-Fernández MA. Impact of different antiretroviral protocols on the dynamics of AIDS progression markers in paediatric patients. XIII International AIDS Conference. Durban (South Africa). July 2000.

53. Resino S, Navarro J, Bellón JM, and Muñoz-Fernández MA. CD4+ T Lymphocyte subpopulations in AR-treated HIV-infected children as markers of HIV-1 replication and immune reconstitution: correlation with CD3, CD4 and CD8 and viral load. 5th ECEAR. Madrid (Spain). June 2000.

54. Resino S, Bellón JM, Gurbindo MD, Ramos JT, León JA, Ruíz-Contreras J, and Muñoz-Fernández MA. Dynamics of progression markers in HIV-1 vertically infected infants with different antiretroviral treatments. 5th ECEAR. Madrid (Spain). June 2000.

55. Navarro J, Abad ML, Resino S, Jiménez JL, Cantó C, Rodríguez D, Lopez F, Esteban M, Muñoz-Fernández MA, E. Fernandez-Cruz for the spanish 2102 team. Effect of a gp 120-depleted inactivated HIV-1 immunogen (REMUNE^TM) on the control of nuclear factor kappa-B activation, cytokine production and augmentation of HIV-1-specific cytotoxic T lymphocytes. 5 th ECEAR. Madrid (Spain).June 2000.

56. Alonso R, Resino S, Bellón JM and Muñoz-Fernández MA. Zidovudine treatment induces a shift to type-2 cytokine responses in HIV-1 infected pregnant women associated to reduced vertical HIV-1 transmission. 5th ECEAR. Madrid (Spain). June 2000.

1999:

57. Resino S, Alonso R, Bellón JM, Muñoz C, Gurbindo D, Miralles P, Segovia P, 1Sampelayo TH and Muñoz-Fernández MA. Risk factors for vertical transmission: role for cytokines. Second Conference of Global Strategies for Prevention of HIV-1 Transmission from Mothers to infants. Montreal (Canada). September 1999.

58. Navarro J, Abad ML, Resino S, Jiménez JL, Carbone J, López F, Muñoz-Fernández MA, and Fernández-Cruz E. Cellular Immune responses to HIV-1 antigens in HIV-1infected subjects undergoing treatment with an inactivated gp-120-depleted HIV-1 immunogen plus antiviral therapy or antiviral therapy alone. 14th Annual Conference on Clinical Immunology & the 5th International Symposium on Clinical Immunology, April 1999. Washington, DC.

59. Muñoz-Fernández MA, Resino S, Bellón JM, Jiménez JL, García D, Puché-Torres A and Gurbindo D. Predictive value of immunological and virological markers for the development of neurological syndromes in HIV infected infants. 14th Annual Conference on Clinical Immunology & the 5th International Symposium on Clinical Immunology, April 1999. Washington, DC.

60. Gurbindo D, Resino S, Bellón JM, Puché-Torres A, García A, Navarro J, and Muñoz-Fernández MA. Prognostic value of CD4 cell percentage viral load and viral phenotype, in naive infants younger than two months of age with human immunodeficiency virus type 1 infection. 14th Annual Conference on Clinical Immunology & the 5th International Symposium on Clinical Immunology, April 1999. Washington, DC.

1998:

61. Abad ML, Alonso R, Resino S, Gurbindo D, Bellón JM, Hernández-Sampelayo T, Muñoz-Fernández MA. Zidovudine and viral load in the mechanism of HIV-1 transmission. Effect of Zidovudine on immunologlobulin production. III Symposium Internacional “Estrategias globales para prevenir la transmisión VIH perinatal” y “SIDA y reproducción”. Valencia 1998.

62. Muñoz-Fernández MA, Gurbindo D, Resino S, Alonso R, Jiménez JL, Obregón E, Navarro J. High viral load in children long term non progressor vertically infected with HIV-1. Immunologic characterization. XII World AISD Conference. Switzerland (Geneva). June 1998.

1997:

63. Muñoz-Fernández MA, Resino S, Navarro J, Jiménez JL, Obregón E, Alonso R, Gurbindo D, Hernández-Sampelayo T and Fernández-Cruz E. Inmunologic and virologic characterization of children vertically infected with HIV-1, with slow or rapid disease progression. A Conference on Global Strategies for the Prevention of the HIV Transmission From Mothers to Infants. Washington DC, September 1997.

64. Gurbindo D, Resino S, Navarro J, Obregón E, Alonso R, Jiménez JL, Abad ML, Fernández-Cruz E and Muñoz-Fernández MA. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell, CD8+ cell. Viral load and progression to AIDS in vertically infected children. A Conference on Global Strategies for the Prevention of the HIV Transmission from Mothers to Infants. Washington DC, September 1997.

65. Muñoz-Fernández MA, Resino S, Navarro J, Obregón E, Jiménez JL, Hernández-Sampelayo T, Gurbindo D and Fernández-Cruz E. Virological and inmunological characterization of long-term survivors in children with vertically acquired HIV-1 infection. IV International Symposium on Clinical Inmunology. Amsterdam, June 1997.

Posts relacionados:

• Redacción y gestión de documentos científicos
• Publicaciones no incluidas en el JCR (ISI)
• Publicaciones internacionales
• Publicaciones científicas
• Proyectos: colaboraciones